VPZ Urges Government Action on Unregulated E-Cigarettes

Nov.01.2022
VPZ Urges Government Action on Unregulated E-Cigarettes
VPZ emphasizes the need for stricter control and licensing of e-cigarettes in the UK, particularly against unregulated imports.

VPZ stated that the current challenge facing the industry is the availability of unregulated imported disposable e-cigarette products in local convenience stores and supermarkets. These products are easily accessible without any regulation or control.


Doug Mutter, President of VPZ, has emphasized the importance of stricter control and regulation of electronic cigarette products. He has urged the Scottish government to take immediate action and implement measures that would require flavored products to only be sold by licensed professional e-cigarette shops that adhere to the Challenge 25 policy and provide consultation for adult smokers and e-cigarette users. In the UK, electronic cigarette products containing nicotine must be registered with the Medicines and Healthcare products Regulatory Agency (MHRA).


However, recent reports have emphasized how unregulated disposable e-cigarette products that are imported are being sold throughout the UK without any control or customer education. This poses a significant threat to the once in a lifetime opportunity for public health.


According to Doug Mutter, electronic cigarettes have had a significant impact in helping more and more people in the UK quit smoking. They have also received the support of authoritative public health agencies as an effective method for treating tobacco dependence. These agencies have recommended the inclusion and encouragement of electronic cigarettes in all treatment approaches.


The American e-cigarette market has been devastated by various factors, including a lack of regulation, posing a serious threat to the UK and potentially damaging the significant progress e-cigarettes have made in improving national health and helping the country reach its smoke-free goals. It is now crucial that we work closely with trade standards, MHRA, border forces, HMRC, NHS, and the Scottish government to address this issue.


If we are to achieve our ambitious goal of a smoke-free generation, we need to take bold and incremental steps to promote and educate the health benefits of electronic cigarettes in advertising.


Researchers from King's College London have found that vaping is more effective in quitting smoking than nicotine replacement therapy. Another report from the Royal College of Physicians Tobacco Advisory Group supports e-cigarettes as an effective treatment for tobacco dependency and suggests that they should be included in all cessation efforts and encouraged. The report also found that the long-term effects of vaping are 95% lower than smoking.


Dr. Javed Khan's recent government-commissioned review outlined recommendations for eliminating smoking and creating a smoke-free generation. The report suggests using e-cigarettes as a way to quit smoking and providing accurate information to consumers about the benefits of making the switch. VPZ hosted an event at their Sauchiehall Street store in Glasgow City Centre, launching Stoptober with interactive carbon monoxide breath tests to educate the public about their health status and reveal the effects of smoking on their bodies.


The event also includes the introduction of their Vape Clinic service, where smokers can receive specialized one-on-one consultations with e-cigarette experts from VPZ to help them quit smoking. These experts are well-trained and possess professional knowledge in interacting with smokers, promoting the health and economic benefits of switching to e-cigarettes.


VPZ, headquartered in Edinburgh, has announced that since its establishment in 2012, it has helped over 700,000 smokers quit smoking. The retailer recently launched a mobile e-cigarette clinic with celebrity ambassador Neil "Razor" Ruddock to help more people quit smoking throughout the UK. They are also calling on the UK government to ban smoking and take a proactive approach to e-cigarettes to improve public health.


Statement:


This article is compiled from third-party information and is intended only for industry communication and learning purposes.


This article does not reflect the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness or accuracy of the content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in the compiler's ability, the translated article may not fully reflect the original text. Therefore, it is recommended to refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan-related, or international statements and positions.


The compilation of information is copyrighted to the original media and authors. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
A study by CDC Foundation researchers found no sustained decline in e-cigarette sales across Alabama, Oklahoma and Louisiana, the first three U.S. states to implement e-cigarette directory laws. Louisiana initially saw a significant sales decline, followed by a rebound and a persistent reduction in product availability. Sales also shifted from nontobacco-flavored disposables toward prefilled cartridges, with Vuse Alto driving much of the increase in menthol cartridges. By April 2025, unlisted products still accounted for more than half of e-cigarette nicotine sales in all three states.
Sep.18
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Global tobacco leaf markets diverged sharply in 2026, with India cutting authorised FCV production amid oversupply while Malawi faced a supply shortfall. U.S. demand improved in some leaf categories, but growers in Brazil, Colombia, Tanzania and Zimbabwe faced pressure from prices, buyer access, costs and weather. With nicotine consumption patterns also shifting, 2027 will test whether supply, demand and grower profitability can move back toward balance.
Oct.26
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives